Brief: Fate Therapeutics Q3 basic EPS USD -0.46
08/11/2023 21:39
Nov 8 (Reuters) - Fate Therapeutics Q3 basic EPS USD -0.46. * Q3 net income USD -45.17 million * Q3 income from operations USD -51.279 million * Q3 operating expenses USD 53.223 million * Q3 collaboration revenue USD 1.944 million
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview